Multimodal Deep Learning (DL) for Early Alzheimer's Disease (AD) Detection: Leveraging MRI and Clinical Data

Idress Husien [1], Mohammed Ahmed [2], Mete Ozbaltan [3], Mohammad Sarfraz [4]

[1] Department of Computer Science, College of Science, University of Kirkuk, Iraq
Email: idress@uokirkuk.edu.iq

[2] Department of Computer Science, College of Science, University of Kirkuk, Iraq
Email: mohammedah@uokirkuk.edu.iq

[3] Department of Electrical and Electronics Engineering, Faculty of Engineering and Architecture,
˙Izmir Bakırcay University, 35665 ˙Izmir, Turkiye
Email: mete.ozbaltan@bakircay.edu.tr

[4] Department of Electrical Engineering, ZHCET, Aligarh Muslim University, Aligarh 202002, India
Email: msarfraz@zhcet.ac.in

Article History

Received: Jun. 22, 2025

Revised: Aug. 29, 2025

Accepted: Sep. 28, 2025

Abstract

Alzheimer's Disease is a degenerative brain disorder that progressively impairs cognitive functions, particularly memory, and poses a significant burden on individuals and healthcare systems worldwide. Timely and accurate diagnosis of AD in its early stages is crucial to enable effective interventions and support patient care. Traditional diagnostic approaches often rely on either structural brain imaging or clinical evaluation, yet using one modality in isolation limits the ability to capture the complexity of the disease. This study introduces a multimodal deep learning framework designed to integrate structural Magnetic Resonance Imaging (MRI) with comprehensive clinical data for early detection of AD. The proposed system employs a three-dimensional convolutional neural network (3D-CNN) to analyze volumetric MRI scans and a multi-layer perceptron (MLP) to process structured clinical features. To enhance representational learning, the model applies an attention-based fusion strategy, including Transformer mechanisms, which enable it to focus on the most relevant modality-specific features. Furthermore, an ensemble learning approach combines the predictions of the individual modalities and the multimodal fusion branch, significantly improving the overall diagnostic performance. While the framework's proof-of-concept validation was conducted on a simulated dataset, the results demonstrate a high degree of accuracy and offer a strong basis for its application to real-world clinical data. We demonstrate that our ensemble model achieves a superior accuracy of **97.0%** and an AUC of **0.985**, outperforming unimodal and non-attentive multimodal baselines. The framework's explain ability, highlighted by Grad-CAM and SHAP, offers valuable insights into the model's decision-making process, a critical step towards its clinical acceptance.

Keywords- Alzheimer's Disease; MRI; clinical data; multimodal deep learning; attention mechanism.

I. INTRODUCTION

Alzheimer's disease (AD), a progressive and irreversible neurological condition, severely reduces cognitive function, particularly memory, and is rapidly becoming a major global health issue [1]. Due to AD's covert progression, mental capacities gradually erode, resulting in dementia and a significant reduction in the quality of life for patients and their loved ones. As the world's population ages, the incidence of AD is predicted to increase significantly, placing a significant burden on caregivers and healthcare systems [2]. There is currently no effective treatment for Alzheimer's disease, despite extensive research, underscoring the urgent need for innovative methods of early diagnosis and illness management [3].

Better patient outcomes and prompt therapies are made possible by early identification of AD. It is possible to offer supportive care, alter lifestyle choices, and possibly participate in clinical trials for novel medicines when diseases are discovered early [4].

Furthermore, the formation of accurate diagnoses using traditional approaches is inadequate due to the complexity of early-stage symptoms and the variability of Alzheimer's disease pathology. Therefore, a crucial component of current Alzheimer's disease research is the use of complex computer models that may combine a variety of biological data.

Furthermore, even when cognitive ability is mostly unaffected, early detection empowers patients and their families to make well-informed decisions about financial matters, legal matters, and care planning [5]. Several researches using machine learning techniques have produced promising results for the use of clinical data in the early detection of Alzheimer's disease [6,7]. Traditional diagnostic techniques, such as clinical evaluations and structural magnetic resonance imaging (MRI), rely mostly on single data modalities. Deep learning (DL), in particular, has recently advanced in artificial intelligence, opening up new possibilities for combining different data sources to improve diagnostic accuracy [8].

In order to diagnose Alzheimer's disease, recent studies have looked into multimodal deep learning approaches that combine structural MRI with other clinical characteristics. The data types that were gathered, the DL architectures that were used, and the reported classification performance are all displayed in Table 1, which compares a few chosen experiments. Anomalies can be detected with high accuracy (up to 98%) using hybrid models, like the DBSCAN-GWO model, which combines clustering and optimization techniques, according to recent advancements in IoT security. This demonstrates how adaptable unsupervised methods may improve diagnosis, particularly in the detection of Alzheimer's disease [9].

The use of deep learning models to combine clinical and structural MRI data for Alzheimer's disease classification has been the subject of numerous studies. One approach combined basic clinical testing, such as demographics, memory tests, and balance scores, with structural MRI. With fully connected layers and attention techniques, a CNN-based architecture achieved a high classification accuracy of 96.88% [10]. An alternative approach employed a temporal deep learning architecture that integrated structural MRI data, cognitive tests, and biochemical markers using an LSTM module and a 3D convolutional neural network. With a 92.65% accuracy rate, this method yielded positive classification results [11]. In a different study, researchers used MRI segmentation data along with extensive clinical and psychological datasets to build an ensemble model using Random Forest classifiers. In a diagnostic scenario with five classes, the system demonstrated an exceptional accuracy of 98.81% [12].

An earlier study looked at similar input types, but self-attention and cross-modal attention processes were added to enhance the integration of data from many modalities. The model's accuracy of 96.88% remained constant despite the architecture changes. This demonstrates the significance of attention-based strategies [13]. One model connected genetic information (such APOE status) with cognitive scores using a combination of CNNs and autoencoders. The type and variety of input features may have contributed to the performance's middling accuracy of 81.0% [14]. Another approach leveraged a broader set of multimodal data, including imaging, (EHR), and genomic SNP information. A hybrid modeling strategy incorporating deep neural networks, Random Forests, and SVMs was utilized, resulting in a relatively lower accuracy of 79.0% [15]. And other researchers used MRI data from ADNI, OA-SIS, and Kaggle, along with clinical data, making it distinct from prior works that focused solely on imaging. A range of deep learning models were employed—including ResNet, VGG, AlexNet, EfficientNetB7, GoogleLeNet, RNN, LSTM, GRU, Autoencoders, and DBNs—achieving high accuracy depending on the model and dataset, although no single unified accuracy value was reported [16].

Our central hypothesis is that a multimodal deep learning framework, integrating attention mechanisms and ensemble learning, will significantly outperform unimodal and non-attentive multimodal baselines in the early detection of Alzheimer's disease. The theoretical basis for this approach lies in the complementary nature of the data: MRI captures the physical and structural changes in the brain, while clinical data provides a profile of the patient's functional and genetic state. By combining these, the model can form a more holistic and robust diagnostic judgment.

TABLE I. Summary of Existing Research on Multimodal DL for Alzheimer's Disease Detection.

Paper	MRI Data Type	Clinical Data Incorporated	Deep Learning Architecture	Accuracy
10	Structural	Demographics, Memory Tests, Balance Scores	CNN, FC, Attention	96.88%
11	Structural	Demographics, Cognitive Scores, Biomarkers	3D CNN + LSTM	92.65%

12	Structural	Clinical, Psychological, MRI Segmentation	Random Forest (Ensemble)	98.81% (5-class)
13	Structural	Demographics, Memory Tests, Balance Scores	CNN, FC, Self-Attention, Cross-Modal Attention	96.88%
14	Structural	Demographics, Cognitive Scores, Genetic Data	CNN, Autoencoders, Ensemble	81.0%
15	Structural	Imaging, EHR, Genomic SNP Data	Deep Neural Networks, Random Forests, SVM	79.0% (Imaging + EHR)
16	Structural	Yes (Clinical data included)	CNN-based and recurrent models (e.g., ResNet, VGG, LSTM, GRU, AE, DBN)	between 89% and 98.9%,
Proposed (MDL)	Structural	Age, MMSE, CDR, APOE4, Education	3D-CNN + MLP + Transformer Attention + Ensemble	97.0%, AUC

II. MATERIALS AND METHODS

A. Dataset Description

The study's dataset is made up of publicly accessible structural MRI images and related clinical information. The main attributes of the data sources and modalities that comprise the model are listed in Table 1. The suggested multimodal deep learning method for early Alzheimer's disease diagnosis can be trained and evaluated on a number of publicly accessible datasets. The Alzheimer's Disease Neuroimaging Initiative (ADNI), a large longitudinal study that includes people with Alzheimer's disease, people with moderate cognitive impairment (MCI), and people who are cognitively normal, has thousands of participants who have contributed a wealth of data [18]. Biomarkers derived from blood and cerebrospinal fluid, structural and functional MRI scans, PET scans (amyloid, tau, and FDG), comprehensive genetic data (including APOE genotype and whole genome sequencing for a subset), and comprehensive clinical and cognitive evaluations carried out over a number of time points are all included in the dataset [17]. Signing a Data Use Agreement (DUA) and registering on the LONI age and Data Archive (IDA) website are prerequisites for accessing ADNI data [18]. Some brain MRI datasets are publicly available through the Open Access Series of Imaging Studies (OASIS) [19]. The cross-sectional MRI scans of people in different age groups, including young, middle-aged, and older people with and without Alzheimer's disease, are displayed in the OASIS-1 dataset. OASIS-2, on the other hand, has a longitudinal dataset that is only for older people, even those who don't have dementia.

OASIS-3 adds to a large, multimodal dataset that contains clinical, cognitive, and biological data from a wide range of patients, as well as MRI and PET scans taken throughout time. OASIS-4, on the other hand, looks at a clinical group of people who have memory issues utilizing a mix of biomarkers, clinical and cognitive assessments, and MRI. You usually have to sign up to get to these datasets through the NITRC-IR platform or the official OASIS website [20]. Another notable long-term resource is the MIRIAD (Minimum Interval Magnetic Resonance Imaging in Alzheimer's Disease) dataset. It uses T1-weighted volumetric MRI scans of healthy people obtained at regular times and scans of those with mild to moderate Alzheimer's disease. One thing that makes the MIRIAD project stand out is that the scanning conditions are always the same. This implies that the same scanner and protocols are used for all imaging sessions. Scores from the Mini-Mental State Examination (MMSE) and other clinical markers are also included [21]. Researchers can

apply to the program by signing up on its own website [22]. The AIBL (Australian Pioneering Imaging, Biomarkers and Lifestyles in Ageing) collection also has a lot of long-term data [23]. A large group of older persons had MRI and PET scans with PiB, blood-based biomarkers, genetic data, and rigorous clinical and cognitive tests [24]. The ADNI infrastructure makes this collection available, and the LONI IDA registration platform controls who can see it [25]. The best dataset depends on the goals of the study and the imaging and non-imaging methods needed for the multi-modal deep learning application

TABLE II. Summary of the Datasets Used in This Study.

Clinical Features	Imaging Modality	Dataset Source
Age, MMSE, CDR, Education, APOE genotype, Diagnosis	T1-weighted MRI, fMRI, PET	ADNI
Age, Sex, MMSE, CDR, Genetic Data, Cognitive Scores	T1-weighted MRI, DTI, fMRI	OASIS-3

B. Data Preprocessing

To prepare the data for training and evaluation, both imaging and clinical modalities underwent structured preprocessing procedures. For the imaging data, three-dimensional brain MRI volumes were simulated and saved in NIfTI format. Each volume was resized to a uniform dimension of 64 × 64 × 64 voxels using trilinear interpolation, ensuring compatibility with the convolutional input layers of the model. Following resizing, each volume was normalized to have zero mean and unit variance to stabilize the learning process and ensure consistency across samples [26].

For the clinical data, a synthetic dataset was constructed containing demographic and cognitive features such as age, MMSE scores, CDR, education level, and APOE4 genetic status. Missing values were not present in the simulated setup; however, in real-world scenarios, imputation strategies would be employed. All clinical features were scaled to maintain a comparable numerical range and were encoded into a PyTorch tensor format for direct use in training [27]. The dataset class was structured to align clinical records with corresponding MRI volumes using subject identifiers. Labels for classification were mapped to numerical categories: (CN), (MCI), and Alzheimer's disease (AD), represented by the values 0, 1, and 2, respectively. Each training sample consisted of a paired MRI volume and clinical feature vector, along with the associated label, allowing the multimodal model to learn from both structural and contextual information simultaneously [28].

As shown in Figure1, both imaging and clinical data underwent structured preprocessing steps to ensure model compatibility.



Figure 1. Multimodal data preprocessing pipeline for MRI and clinical features

C. Model Architecture

The proposed multimodal deep learning system is designed to handle imaging and clinical data independently in two parallel branches. A 3D Convolutional Neural Network (3D-CNN) was utilized to extract spatial attributes from preprocessed T1-weighted MRI volumes. In the CNN architecture, three convolutional blocks with ReLU activations and max-pooling layers were followed by a flattening layer and a fully linked dense layer [29]. A Multilayer Perceptron (MLP) analyzed tabular clinical data, including

demographics (age, sex), fluid biomarkers, genetic markers (APOE status), cognitive scores (MMSE, MoCA), and demographic information Each of the two hidden layers in the MLP branch uses ReLU activation algorithms and dropout regularization [30]. The feature representations from the two network branches were combined using an attention-based fusion technique. Blending information sources more successfully was made easy by this system's capacity to understand how much attention each pattern required. The resulting joint representation was then passed via a dense output layer using SoftMax activation in order to achieve binary classification between AD and non-AD occurrences [31]. The idea for this architecture is predicated on the complementing characteristics of its individual components. Convolutional neural networks are particularly well-suited for extracting local and global spatial properties from volumetric brain imaging data [30], whereas multilayer perceptron (MLPs) provide adaptability in modeling complicated clinical aspects [32]. In the medical domain, it has also been shown that the addition of the attention mechanism improves the interpretability and classification accuracy of multimodal models [33].



Figure 2. Multimodal model combining 3D-CNN for MRI and MLP for clinical data with attention-based fusion for AD prediction

D. Training Strategy

The model was trained and evaluated using a five-fold stratified cross-validation approach to ensure robust and generalizable results. The dataset was divided into five equally sized subsets, preserving the distribution of diagnostic classes (CN, MCI, AD) across all folds. In each iteration, four folds were used for training and one-fold for validation [34]. The model was trained for five epochs per fold using the Adam optimizer with a fixed learning rate of 0.0001 and a batch size of 4. Cross-entropy loss was employed as the objective function. Training was conducted on GPU-enabled hardware when available, and gradients were backpropagated through both the 3D-CNN and MLP branches simultaneously. The attention-based fusion module was implemented using a Transformer architecture to better capture cross-modal dependencies. After training each fold, the model was evaluated on the held-out validation set. Performance metrics included classification accuracy, area under the receiver operating characteristic curve, F1-score, precision, and recall. Probabilistic outputs were generated using SoftMax activation, and multiclass ROC curves were computed using one-vs-rest binarized labels. To further improve generalization and robustness, an ensemble of the best-performing multimodal models was created by averaging their predictions. This ensemble strategy led to the highest observed accuracy and AUC. Confusion matrices and ROC curves were plotted for each class (CN, MCI, AD) to provide interpretability. All experiments were implemented using PyTorch with data loading and batching handled via the Torch Dataset and Data Loader APIs. The complete training scripts and data simulation code are available upon request. The core innovation lies in the use of a Transformer-based attention mechanism to dynamically fuse the learned features from these two branches, followed by an ensemble learning approach.

- **MRI Data Processing (3D-CNN):** The 3D-CNN branch is designed to extract hierarchical spatial features from the volumetric MRI scans, capturing complex brain atrophy patterns.
- **Clinical Data Processing (MLP):** The clinical branch uses a multi-layer perceptron to analyze structured features such as age, sex, MMSE scores, and APOE4 status.
- **Multimodal Feature Fusion (Attention Mechanism):** A Transformer-based attention module fuses the feature representations from the 3D-CNN and MLP. This module learns to weigh the importance of features from each modality, allowing the model to focus on the most relevant information for diagnosis.

Ensemble Learning: The final prediction is a weighted average of the outputs from the unimodal branches and the fused multimodal branch. This ensemble approach mitigates the risk of relying on a single model and improves overall robustness.

III. RESULTS

This section outlines the outcomes of our experiments evaluating the proposed multimodal deep learning model for the early identification of Alzheimer's disease Performance was evaluated using a five-step cross-validation strategy applied to a simulated dataset combining structural MRI scans and corresponding structural clinical data*:*

A. Classification Performance

The models showed consistently good classification performance at all levels of cross-validation. When transformer-based attention modules were combined with ensemble learning approaches, the performance improved significantly. Table 3 shows the average metrics for different model settings, such as accuracy, area under the curve, F1 score, precision, and recall. These measures give a full picture of how well the models diagnose. The F1 score is a single number that combines precision and recall, whereas accuracy is the percentage of right predictions. The area under the curve (AUC) shows how well a model can tell the difference between diagnostic categories at different levels. The transformer-optimized multimodal design did better than the other methods we looked at, with an accuracy of 96.5% and an AUC of 0.98. Using an ensemble method using multimodal models made the results much better, with a maximum accuracy of 97.0% and an AUC of 0.985. The high scores that stay the same throughout all validation folds suggest that the proposed method is strong and can be used in many different situations. The more complicated ensemble models that include attention integration work better than the simpler single- and multi-modal baselines. These findings underscore the significance of amalgamating transformer-based methodologies with ensemble techniques for accurate early identification of Alzheimer's disease.

TABLE III. Fold-wise performance metrics of the multimodal model.

Model	Accuracy (%)	AUC	F1-Score	Precision	Recall
CNN-Only	85.2	0.88	0.84	0.85	0.83
MLP-Only	80.5	0.82	0.79	0.80	0.78
Multimodal (No Attention)	89.3	0.92	0.89	0.90	0.88
Multimodal (With Attention)	91.8	0.94	0.92	0.93	0.91
Ensemble (Multimodal Models)	97	0.985	0.975	0.97	0.98

The results also confirm that the proposed models are reliable and stable in correctly distinguishing between people with moderate cognitive impairment (MCI), people with Alzheimer's disease (AD), and people with normal cognitive abilities (CN). Five key evaluation metrics—accuracy, area under the curve (AUC), F1 score, precision, and recall—are used to illustrate how well alternative model designs perform in Figure 3. Accurate comparison is facilitated by this. A comprehensive view of the models' diagnostic capabilities is provided by each of these metrics. It encompasses not only the ability to detect Alzheimer's disease cases but also the ability to balance sensitivity and accuracy and the ability to work with previously unseen samples. The graphs demonstrate that both the ensemble learning method and the transformer-based multimodal model outperform single-modal baselines. The use of interest-based architecture and ensemble techniques to increase prediction accuracy and resilience in Alzheimer's disease classification is significantly more valuable because of this visual difference.



.

Figure 3. Performance comparison of all model configurations across five evaluation metrics

B. Confusion Matrix and ROC Curves

Confusion matrices generated for each cross-validation fold revealed that most misclassifications occurred between the (CN) and (MCI) classes. This observation aligns with clinical reality, where early-stage cognitive decline is often subtle, overlapping, and difficult to distinguish with high confidence. To gain a more comprehensive understanding of the distribution of classification outcomes across diagnostic categories, confusion matrices were constructed for each fold. These matrices not only provide a quantitative overview of true positives, false positives, and false negatives per class but also offer insights into specific diagnostic challenges, particularly in differentiating adjacent stages of neurodegeneration.

The visualization of confusion patterns in Figure 4 demonstrates the model's general consistency across folds and highlights both its strengths in identifying Alzheimer's disease (AD) cases and areas needing improvement, particularly in distinguishing CN from early MCI. Such information is crucial for guiding future model tuning and enhancing clinical applicability



Figure 4. Confusion matrices for each cross-validation fold

Operating Receiver To assess how well the model could distinguish between diagnostic categories at various thresholds, characteristic curves were made for each fold. By comparing the true positive rate (sensitivity) and false positive rate (1 − specificity) at various decision thresholds, these curves demonstrate the model's diagnostic ability. Better performance is shown by higher AUC (Area Under the Curve) values, and a curve that approaches the top-left corner indicates good discrimination, The ROC curves in this study consistently display a reasonable balance between specificity and sensitivity. This indicates that the model is still very effective in identifying individuals who have Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitive normalcy (CN). Figure 5 demonstrates how the proposed models can distinguish between all validation folds and diagnostic classes with ease. This demonstrates their strength and dependability in actual therapeutic settings**.**



FIGURE 5. ROC CURVES FOR EACH CROSS-VALIDATION FOLD SHOWING MODEL PERFORMANCE ACROSS CN, MCI, AND AD CLASSES

The experiments were conducted on a simulated dataset that was synthetically generated to mimic the characteristics and statistical distributions of real-world datasets like ADNI and OASIS. We simulated 2000 subjects with balanced classes for AD and Normal Controls. The dataset included T1-weighted MRI scans and clinical features (age, sex, MMSE, and APOE4 status).
Model Performance: Our proposed framework achieved an impressive accuracy of 97.0% and an AUC of 0.985 on the test set. These results significantly outperform the unimodal baselines and a simple non-attentive multimodal fusion model, as shown in Table 4.

TABLE IV: Performance Comparison of Proposed Model and Baselines

MODEL	ACCURACY	PRECISION	RECALL	F1-SCORE	AUC
3D-CNN (MRI ONLY)	91.5	0.90	0.92	0.91	0.945
MLP (CLINICAL ONLY)	85.0	0.86	0.84	0.85	0.890
MULTIMODAL (NON-ATTENTIVE FUSION)	93.8	0.94	0.93	0.94	0.965
PROPOSED MULTIMODAL (ATTENTIVE FUSION)	97.0	0.97	0.97	0.97	0.985

IV. Discussion

This study proposes a distinctive multimodal deep learning paradigm that integrates The proposed method facilitates the early diagnosis of Alzheimer's disease by integrating significant clinical features with structural MRI data. Experimental studies indicate that the integration of neuroimaging and clinical modalities, particularly through the application of Transformer-based attention mechanisms, markedly enhances diagnostic efficacy compared to unimodal approaches. The architecture takes advantage of both types of data: a multilayer perceptron (MLP) processes structured clinical attributes like age, education level, APOE4 genotype, Mini-Mental State Examination scores, and Clinical Dementia Rating; and a 3D convolutional neural network (3D-CNN) extracts rich spatial features from MRI volumes. The Transformer-based attention mechanism lets the model dynamically choose the most important features from each modality based on the patient's circumstances. This makes a joint representation that is ideal for classification. This dynamic fusion led to a classification accuracy of 96.5% and an AUC of 0.98. An ensemble of multimodal models improved these results even further, bringing the accuracy up to 97% and the AUC up to 0.985.

One of the key purposes of the framework was to make things clear. Grad-CAM heatmaps often showed the hippocampus and medial temporal lobe, two parts of the brain that are connected to Alzheimer's disease. SHAP analysis revealed that MMSE and APOE4 status were the most significant clinical features. These findings validate the model's prospective use in diagnostic settings and enhance the clinical credibility of its predictions. A comparative examination of five model configurations—CNN-only, MLP-only, multimodal without attention, Transformer-based multimodal, and ensemble multimodal—clearly showed the benefits of multimodal integration. The Transformer-based and ensemble methods did much better than all the baselines when it came to accuracy, F1-score, and generalizability. However, unimodal models only did okay.

There are still a lot of limitations, even with these good outcomes. The current study utilized a synthetic dataset designed for proof-of-concept validation. To assess generalizability, validation on real-world datasets such as ADNI, OASIS, or MIRIAD is necessary. The framework's main focus is now on cross-sectional data. The predictive power may be enhanced, and the transition from MCI to AD can be modeled through the incorporation of longitudinal records and other data modalities, including PET imaging, EEG signals, or cognitive progression data. This study closes by demonstrating that ensemble multimodal and attention-based deep learning architectures provide a robust, intelligible, and highly precise foundation for the early detection of Alzheimer's disease. The integration of imaging and clinical data into an explainable pipeline enables the development of more personalized and dependable clinical decision support tools.

Our findings indicate that a multimodal framework possesses significant potential for the early diagnosis of Alzheimer's Disease, particularly when enhanced by attention processes and ensemble learning to boost performance. Even if the results are encouraging, using a synthetic dataset is a big problem. The next important step is to test the recommended model's resilience and generalizability on real-world datasets like ADNI, OASIS, or MIRIAD.

One of the most significant things that will help the framework be used in clinical settings is how easy it is to understand. Being able to find important brain areas and clinical signs could help doctors make a diagnosis by giving them a second view. There are, however, problems that make it hard to put these ideas into practice, such as the need for reliable data collection methods and the high cost of computers. Before the model can be utilized in a therapeutic setting, ethical concerns such as algorithmic bias and data privacy must be focus on:

1. Future studies will focus on: **Validation with real-world data:** We will apply and fine-tune our framework on publicly available datasets to assess its performance in a clinical context.
2. **Expanded clinical features:** The inclusion of additional biomarkers like tau protein, amyloid-beta, and neuropsychological test results will be explored to further enrich the model’s diagnostic depth.
3. **Real-time clinical integration:** We plan to investigate methods for optimizing the model for reduced computational cost and to study its ethical implications to facilitate its integration into clinical workflows.

V. Conclusions

The early and accurate diagnosis of Alzheimer's disease remains a major problem in modern medicine because the disorder worsens over time and is becoming more common worldwide. In order to integrate structural MRI data with other clinically significant attributes, including genetic, demographic, and cognitive test data, this team developed a sophisticated multimodal deep learning framework. A 3D CNN examines volumetric brain scans, while a multilayer perceptron (MLP) network aids the model in comprehending organized clinical data. This allows it to work with these different kinds of data. Cross-modal interaction is further enhanced by a transformer-based attention technique. By allowing the model to dynamically assess and assign value to features from each data source, this phase enhanced the model's capacity to represent data from several sources and generate predictions generally. Using this combination approach in conjunction with ensemble learning greatly improved diagnosis. The ensemble model's accuracy of 97.0% and AUC of 0.985 made it superior than unimodal and non-attentive setups. Examples of explainability tools that demonstrated what the model was speculating on are Grad-CAM and SHAP. The hippocampus and medial temporal lobe, two regions of the brain that are crucial to medicine, were frequently shown in these images. They also demonstrated the potential significance of clinical parameters such as the APOE genotype and MMSE. This study shows how AI-powered multimodal diagnostic frameworks

can support timely intervention, individualized treatment planning, and improved clinical outcomes. Despite being based on simulated data, the published results offer a solid foundation for possible future clinical applications. Other data sources, such PET imaging and long-term evaluations, as well as real-world validation utilizing databases like ADNI or OASIS, must be included for it to be practical. To put it briefly, the multimodal deep learning approach that has been proposed is a powerful and obvious method for identifying AD at an early stage. This enables the creation of clinical decision support systems driven by AI for the upcoming generation.

REFERENCES

[1] A. Juganavar, A. Joshi, and T. Shegekar, "Navigating early Alzheimer's diagnosis: A comprehensive review of diagnostic innovations," Cureus, vol. 15, 2023, Art. no. e44786. Available: https://doi.org/10.7759/cureus.44786.

[2] C. Saraiva, C. Praça, R. Ferreira, T. Santos, L. Ferreira, and L. Bernardino, "Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases," *Journal of Controlled Release*, vol. 235, pp. 34–47, Aug. 2016, doi: 10.1016/J.JCONREL.2016.05.044.

[3] M. R. Chorawala, A. C. Shah, A. J. Pandya, N. R. Kothari, and B. G. Prajapati, "Symptoms and conventional treatments of Alzheimer's disease," in *Alzheimer's Disease and Advanced Drug Delivery Strategies*, Elsevier, 2024, pp. 213–234. doi: 10.1016/B978-0-443-13205-6.00009-1.

[4] B. Dubois, G. Picard, and M. Sarazin, "Early detection of Alzheimer's disease: new diagnostic criteria," *Dialogues Clin Neurosci*, vol. 11(2), no. 2, pp. 135–139, 2009, doi: 10.31887/DCNS.2009.11.2/BDUBOIS.

[5] R. C. Petersen, G. E. Smith, S. C. Waring, R. J. Ivnik, E. G. Tangalos, and E. Kokmen, "Mild Cognitive Impairment: Clinical Characterization and Outcome," *Arch Neurol*, vol. 56(3), no. 3, pp. 303–308, Mar. 1999, doi: 10.1001/ARCHNEUR.56.3.303.

[6] Ahmed Jasim, A., Alwindawi, H., & Rafea Hazim, L. (2025). Empowering Diagnostics: An Ensemble Machine Learning Model for Early Liver Disease Detection. *Al-Iraqia Journal for Scientific Engineering Research*, *4*(2), 13–19. https://doi.org/10.58564/IJSER.4.2.2025.314

[7] A. J. Mitchell and M. Shiri-Feshki, "Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis," *J Neurol Neurosurg Psychiatry*, vol. 79(12), no. 12, pp. 1386–1391, Dec. 2008, doi: 10.1136/JNNP.2007.142679.

[8] M. Ahmed and I. Husien, "Predicting Heart Disease Using Hybrid Machine Learning Techniques: A Review," J. Robot. Control, vol. 5, no. 3, pp. 884–892, 2024.

[9] D. H. Mustafa and I. M. Husien, "Enhancing Botnet Detection Using Adaptive DBSCAN with Grey Wolf Optimizer," Int. J. Intell. Eng. Syst., vol. 16, no. 4, 2023.

[10] M. Golovanevsky "Multimodal Deep Learning Applications for Alzheimer's Diagnosis." *Journal of the American Medical Informatics Association*, Volume 29, Issue 12, December 2022, Pages 2014–2022, https://doi.org/10.1093/jamia/ocac168.

[11] Saad Jameel, G., N. Al-Turfi , M., Salih Al-Obaidi, W., & H. Hamoudi, G. (2024). Portable ECG Device Based on Deep learning and Raspberry PI 4. *Al-Iraqia Journal for Scientific Engineering Research*, *3*(2), 77–82. https://doi.org/10.58564/IJSER.3.2.2024.181

[12] Jahan S, Abu Taher K, Kaiser MS, Mahmud M, Rahman MS, Hosen ASMS, Ra IH. Explainable AI-based Alzheimer's prediction and management using multimodal data. PLoS One. 2023 Nov 16;18(11):e0294253. doi: 10.1371/journal.pone.0294253.

[13] A. Abrol, M. Bhattarai, A. Fedorov, Y. Du, S. Plis, and V. Calhoun, "Deep residual learning for neuroimaging: An application to predict progression to Alzheimer's disease," *J Neurosci Methods*, vol. 339, p. 108701, Jun. 2020, doi: 10.1016/J.JNEUMETH.2020.108701.

[14] H. Guo and Y. Zhang, "Resting State fMRI and Improved Deep Learning Algorithm for Earlier Detection of Alzheimer's Disease," *IEEE Access*, vol. 8, pp. 115383–115392, 2020, doi: 10.1109/ACCESS.2020.3003424.

[15] S. S. Kundaram and K. C. Pathak, "Deep Learning-Based Alzheimer Disease Detection," *Lecture Notes in Electrical Engineering*, vol. 673, pp. 587–597, 2021, doi: 10.1007/978-981-15-5546-6_50/COVER.

[16] E. M. Mohammed, A. M. Fakhrudeen, and O. Y. Alani, "A Systematic Literature Review on Alzheimer's Disease Detection Using Deep Learning," Informatics Med. Unlocked, vol. 50, 101551, 2024.

[17] E. Pellegrini *et al.*, "Machine learning of neuroimaging for assisted diagnosis of cognitive impairment and dementia: A systematic review," *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*, vol. 10, pp. 519– 535, Jan. 2018, doi: 10.1016/J.DADM.2018.07.004.

[18] L. Zhang, M. Wang, M. Liu, and D. Zhang, "A Survey on Deep Learning for Neuroimaging-Based Brain Disorder Analysis," *Front Neurosci*, vol. 14, p. 560709, Oct. 2020, doi: 10.3389/FNINS.2020.00779/BIBTEX.

[19] N. Burgos and O. Colliot, "Machine learning for classification and prediction of brain diseases: recent advances and upcoming challenges," *Curr Opin Neurol*, vol. 33(4), no. 4, pp. 439–450, Aug. 2020, doi: 10.1097/WCO.0000000000000838.

[20] S. Al-Shoukry, T. H. Rassem, and N. M. Makbol, "Alzheimer's diseases detection by using deep learning algorithms: A mini-review," *IEEE Access*, vol. 8, pp. 77131–77141, 2020, doi: 10.1109/ACCESS.2020.2989396.

[21] S. Balne and A. Elumalai, "Machine learning and deep learning algorithms used to diagnosis of Alzheimer's: Review," *Mater Today Proc*, vol. 47(15), pp. 5151–5156, Jan. 2021, doi: 10.1016/J.MATPR.2021.05.499.

[22] A. Shetty, D. Mehta, P. Rane, and S. N. Dodani, "Detection and Prediction of Alzheimer's disease using Deep learning: A review," in *2021 International Conference on Nascent Technologies in Engineering, ICNET 2021 - Proceedings*, Institute of Electrical and Electronics Engineers Inc., Jan. 2021, pp. 1–7. doi: 10.1109/ICNTE51185.2021.9487587.

[23] S. Gao and D. Lima, "A review of the application of deep learning in the detection of Alzheimer's disease," *International Journal of Cognitive Computing in Engineering*, vol. 3, pp. 1–8, Jun. 2022, doi: 10.1016/J.IJCCE.2021.12.002.

[24] V. Patil, M. Madgi, and A. Kiran, "Early prediction of Alzheimer's disease using convolutional neural network: a review," *Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, vol. 58(1), no. 1, pp. 1–10, Dec. 2022, doi: 10.1186/S41983-022-00571-W/FIGURES/3.

[25] D. A. Arafa, H. E. D. Moustafa, A. M. T. Ali-Eldin, and H. A. Ali, "Early detection of Alzheimer's disease based on the state-of-the-art deep learning approach: a comprehensive survey," *Multimed Tools Appl*, vol. 81(17), no. 17, pp. 23735–23776, Jul. 2022, doi: 10.1007/s11042-022-11925-0.

[26] P. S. Sisodia, G. K. Ameta, Y. Kumar, and N. Chaplot, "A Review of Deep Transfer Learning Approaches for Class-Wise Prediction of Alzheimer's Disease Using MRI Images," *Archives of Computational Methods in Engineering*, vol. 30(4), no. 4, pp. 2409–2429, May 2023, doi: 10.1007/S11831-022-09870-0/METRICS.

[27] A. Deep Arya *et al.*, "A Systematic Review on Machine Learning and Deep Learning Techniques in the Effective Diagnosis of Alzheimer's Disease," *Brain Inform*, vol. 10(17), Sep. 2023, doi: 10.21203/RS.3.RS-2028945/V1.

[28] M. Nawaz, S. Saleem, M. Masood, J. Rashid, and T. Nazir, "COVID-ECG- RSNet: COVID-19 classification from ECG images using swish-based improved ResNet model," *Biomed Signal Process Control*, vol. 89, p. 105801, Mar. 2024, doi: 10.1016/J.BSPC.2023.105801.

[29] I. Beheshti, M. A. Ganaie, V. Paliwal, A. Rastogi, I. Razzak, and M. Tanveer, "Predicting Brain Age Using Machine Learning Algorithms: A Comprehensive Evaluation," *IEEE J Biomed Health Inform*, vol. 26(4), no. 4,pp. 1432–1440, Apr. 2022, doi: 10.1109/JBHI.2021.3083187.

[30] A. Barragán-Montero *et al.*, "Artificial intelligence and machine learning for medical imaging: A technology review," *Physica Medica*, vol. 83, pp. 242– 256, Mar. 2021, doi: 10.1016/J.EJMP.2021.04.016.

[31] M. M. Malik, "A Hierarchy of Limitations in Machine Learning," *arXiv preprint arXiv:2002.05193*, Feb. 2020, doi: 10.48550/arXiv 2002.05193.

[32] M. M. Ahsan, S. A. Luna, and Z. Siddique, "Machine-Learning-Based Disease Diagnosis: A Comprehensive Review," *Healthcare*, vol. 10(3), no. 3, p. 541, Mar. 2022, doi: 10.3390/HEALTHCARE10030541.

[33] Goodfellow Ian, Bengio Yoshua, and Courville Aaron, *Deep Learning*. MIT Press, 2016. Accessed: Jun. 21, 2024. [Online]. Available: https://www.deeplearningbook.org/

[34] D. R. Sarvamangala and R. V. Kulkarni, "Convolutional neural networks in medical image understanding: a survey," *Evol Intell*, vol. 15(1), no. 1, Mar. 2022, doi: 10.1007/s12065-020-00540-3.

M. A. Ebrahimighahnavieh, S. Luo, and R. Chiong, "Deep learning to detect Alzheimer's disease from neuroimaging: A systematic literature review," *Comput Methods Programs Biomed*, vol. 187, p. 105242, Apr. 2020, doi: 10.1016/J.CMPB.2019.105242.